Advertisement
Advertisement

ENLV

ENLV logo

Enlivex Ltd. Ordinary Shares

0.72
USD
Sponsored
+0.02
+2.37%
May 21, 15:59 UTC -4
Closed
exchange

After-Market

0.74

+0.02
+3.44%

Enlivex Ltd. Ordinary Shares Profile

About

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.

Info & Links

CEO

Oren Hershkovitz

Headquarters

14 Einstein Street
Ness Ziona, L3 7403618, ISRAEL

Industry

Medical Drugs

Sector

Medical

Website

www.enlivex.com

Auditor

Yarel & Partners

Share holders

--

Employees

34

Enlivex Ltd. Ordinary Shares Statistics

Valuation Measures

Market Capitalization2

179.58M

Enterprise Value

178.07M

Enterprise Value/EBITDA(ttm)

-12.12

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.12

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

248.08%

Return on Invested Capital(ttm)

25.08%

Return on Assets(ttm)

206.39%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-14.70M

Net Income Available to Common(ttm)

1.24B

Diluted EPS(ttm)

-0.55

Share Statistics

Beta (5Y Monthly)

1.68

52-Week Change

-27.25%

S&P 500 52-Week Change

27.39%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

237.38M

Dividend Yield

0.00%

Float4

208.23M

% Held by Insiders

12.28%

% Held by Institutions

1.02%

Balance Sheet

Total Cash(mrq)

1.74B

Total Cash Per Share(mrq)

7.32

Total Debt(mrq)

383.00K

Total Debt/Equity(mrq)

0.02%

Current Ratio(mrq)

193.24%

Quick Ratio(mrq)

193.24%

Book Value Per Share(mrq)

8.15

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.21

Free Cash Flow(ytd)

-10.48M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement